FLX Bio, Inc., a South San Francisco, Calif. – based biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system against cancer, completed a $60m Series C financing.
Backers included new investors from GV (formerly Google Ventures) and others as well as existing investors The Column Group, Kleiner Perkins, Topspin Partners and Celgene Corporation.
The company intends to use the funds to advance its pipeline of small molecule immuno-oncology compounds focused on regulatory T cell and tumor myeloid cell modulation.
Led by Brian Wong, M.D., Ph.D., President and CEO, and Bill Ho, M.D., Ph.D., Chief Medical Officer, FLX Bio is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, the company’s small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment.
Its lead candidate, FLX475 is an oral, small molecule antagonist a CCR4 inhibitor, entered Phase 1 studies in December 2017 with the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers.